Recursion Pharmaceuticals (RXRX) News Today $6.03 -0.06 (-0.99%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Is Recursion Pharmaceuticals Stock a Millionaire Maker?December 21 at 9:00 AM | fool.com1 Artificial Intelligence (AI) Stock That Could Soar in 2025December 21 at 8:25 AM | fool.com105,018 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Wellington Management Group LLPWellington Management Group LLP bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 105,018 shares of the company's stock, vDecember 21 at 3:40 AM | marketbeat.comRecursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesDecember 20 at 4:05 PM | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.7% - Time to Buy?December 20 at 1:29 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% Higher - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% Higher - Here's What HappenedDecember 19 at 1:47 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - What's Next?December 19 at 11:03 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.4% - Time to Sell?December 18 at 2:42 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5% - Here's WhyDecember 17, 2024 | marketbeat.comState Street Corp Acquires 4,120,685 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)State Street Corp boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 47.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,870,272 shares of the company's stock afteDecember 17, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.8% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.8% - Should You Buy?December 16, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Should You Buy?December 16, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 0.4% - Here's What HappenedDecember 13, 2024 | marketbeat.comTD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)December 12, 2024 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3% - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3% - Here's What HappenedDecember 12, 2024 | marketbeat.comRecursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early TrialsDecember 12, 2024 | insidermonkey.comRecursion: Transforming Drug Discovery With Its AI-Powered Drug Development PlatformDecember 12, 2024 | seekingalpha.comPromising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comCautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming MilestonesDecember 12, 2024 | markets.businessinsider.comWhy Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short SellersDecember 12, 2024 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.7% - Time to Sell?December 11, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Should You Buy?December 11, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday.December 11, 2024 | marketbeat.comUnpacking the Latest Options Trading Trends in Recursion PharmaceuticalsDecember 11, 2024 | benzinga.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2% - Here's WhyDecember 10, 2024 | marketbeat.comRecursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityDecember 9, 2024 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 21.5% - Time to Buy?December 9, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 288,926 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Charles Schwab Investment Management Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 17.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,940,680 shares of the company's stoDecember 9, 2024 | marketbeat.comFmr LLC Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Fmr LLC grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 2.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 8,363,530 shares of the company's stock after acquiring an additional 170,810 shares during the quarter.December 8, 2024 | marketbeat.comBenjamin Edwards Inc. Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Benjamin Edwards Inc. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13,196.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 162,481 sharesDecember 7, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 6.7% - Should You Buy?December 6, 2024 | marketbeat.comRecursion Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw unusually large options trading on Friday. Traders bought 22,003 call options on the stock. This represents an increase of 239% compared to the average daily volume of 6,490 call options.December 6, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.9% - Here's What HappenedDecember 5, 2024 | marketbeat.comJim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’December 4, 2024 | insidermonkey.comNVIDIA Invested in These 2 AI Stocks, Should You? Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.December 2, 2024 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.6% - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% Higher - Here's What HappenedNovember 29, 2024 | marketbeat.com2 Innovative Stocks That Could Deliver Outsize ReturnsNovember 22, 2024 | fool.comRecursion Pharmaceuticals’ Strategic Acquisition and Leadership ChangesNovember 22, 2024 | markets.businessinsider.comHold Rating Recommended for Recursion Pharmaceuticals Post-Merger with Exscientia: Upside Potential Amidst Clinical UncertaintiesNovember 21, 2024 | markets.businessinsider.comStrategic Mergers and Financial Strength: Recursion Pharmaceuticals’ Path to GrowthNovember 21, 2024 | markets.businessinsider.comRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNovember 20, 2024 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month Low - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's WhyNovember 19, 2024 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 SharesNovember 15, 2024 | insidertrades.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% After Insider SellingRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.9% on Insider SellingNovember 15, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 220,302 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Sumitomo Mitsui Trust Group Inc. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,766,728 shares of the coNovember 15, 2024 | marketbeat.comPier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Pier 88 Investment Partners LLC raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 442.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,910 shares of the company's stock after puNovember 14, 2024 | marketbeat.comRecursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13, 2024 | globenewswire.comRecursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenNovember 13, 2024 | markets.businessinsider.comRecursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model GardenNovember 12, 2024 | globenewswire.comBaillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Baillie Gifford & Co. trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,239,870 shares of the company's stock afNovember 12, 2024 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.410.60▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼107▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ascendis Pharma A/S News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Nuvalent News Today Blueprint Medicines News Today Elanco Animal Health News Today Cytokinetics News Today Viking Therapeutics News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXRX Stock Alerts